About prokidney corp - PROK
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
PROK At a Glance
ProKidney Corp.
2000 Frontis Plaza Boulevard
Winston-Salem, North Carolina 27103
| Phone | 1-336-999-7028 | Revenue | 893.00K | |
| Industry | Biotechnology | Net Income | -68,986,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 1,075.0% | |
| Fiscal Year-end | 12 / 2026 | Employees | 231 | |
| View SEC Filings |
PROK Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 335.982 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.467 |
| Enterprise Value to Sales | 1,507.324 |
| Total Debt to Enterprise Value | 0.003 |
PROK Efficiency
| Revenue/Employee | 3,865.801 |
| Income Per Employee | -298,640.693 |
| Receivables Turnover | 0.792 |
| Total Asset Turnover | 0.002 |
PROK Liquidity
| Current Ratio | 9.13 |
| Quick Ratio | 9.13 |
| Cash Ratio | 8.783 |
PROK Profitability
| Gross Margin | -540.761 |
| Operating Margin | -18,442.217 |
| Pretax Margin | -16,931.467 |
| Net Margin | -7,725.196 |
| Return on Assets | -17.741 |
| Return on Equity | N/A |
| Return on Total Capital | 6.85 |
| Return on Invested Capital | N/A |
PROK Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -0.401 |
| Total Debt to Total Assets | 1.203 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -0.294 |